Nearly half of American hospitals aren’t taking key steps to prevent Clostridium difficile infection-despite strong evidence that such steps work, according to a new study published online in Infection Control & Hospital Epidemiology.
Dr SaintNearly half of American hospitals aren’t taking key steps to prevent Clostridium difficile infection-despite strong evidence that such steps work, according to a new study published online in Infection Control & Hospital Epidemiology.
The current study was part of an ongoing panel survey that began in 2005 when researchers from the University of Michigan Medical School and VA Ann Arbor Healthcare System asked hospitals across the United States what practices they are using to prevent common healthcare-associated infections.
WATCH: Sanjay Saint, MD, MPH, interview on hospital-acquired infections
Sanjay Saint, MD, MPH, chief of medicine, VA Ann Arbor Healthcare System, George Dock Professor of Internal Medicine, University of Michigan Medical School (U-M), and his colleagues from the Patient Safety Enhancement Program, a joint U-M and VA Ann Arbor Healthcare System program, surveyed infection control leaders at hospitals, as part of an ongoing project that started in 2005. They asked hospitals what practices they are using to prevent common healthcare-associated infections. More than 70% of the 571 hospitals that received the survey answered it.
Related: Cigarette smoke makes MRSA more aggressive
The survey sample included a stratified random sample of non-federal general medical and surgical hospitals with 50 or more beds and with intensive care beds. Surveys were mailed to all hospitals along with a cover letter, a pre-paid return envelope, and a $10 incentive. Survey reminders were sent after the initial mailing. The present survey included questions related to C diff infection prevention. Respondents were asked how frequently certain C diff infection practices were used for adults in their acute care facility.
“Healthcare-associated infections are common, costly and potentially life-threatening. The findings of this study highlight that a key prevention practice for C diff infection-antimicrobial stewardship-is lacking in about half of US hospitals despite the perceived high strength of evidence to support such programs,” according to Dr Saint.
NEXT: 3 steps formulary managers can do
“First, most US hospitals reported using a surveillance system to monitor for C diff infections among their patients. Second, reported use of several recommended practices is very high, along with the corresponding perceived strength of evidence for many of these practices. Finally, the gap between our respondents’ reported regular use of antimicrobial stewardship and their perceived strength of evidence to support antimicrobial stewardship was the highest of any practice.”
Related:Time to show and tell about antibiotic stewardship programs
According to Dr Saint, there are 3 steps formulary managers can do to help prevent infection:
Healthcare-associated infections are a major cause of illness and death in hospitalized patients and preventing healthcare-associated infection is a global challenge, according to Dr Saint.
NEXT: Prevalence of hospital-acquired infections
According to the World Health Organization, worldwide, the prevalence of healthcare-associated infections in developed countries and undeveloped countries range from 5.1% to 11.6% and 5.7% to 19.1%, respectively. In the United States, roughly 2 million such infections occur annually, resulting in approximately 99,000 deaths and estimated annual direct medical costs ranging between $28.4 and $33.8 billion.
Related:741 drugs in antibiotic pipeline, few first-in-class
Last fall, the White House set a goal of reducing C diff infections by 50% by 2020, as part of its
. The Centers for Disease Control and Prevention has also targeted C. diff as a key threat to public health. And hospitals’ C diff infection rates among Medicare participants are publicly reported on the Hospital Compare website operated by the U.S. Department of Health and Human Services.
Sanjay Saint, MD, MPH, chief of medicine, VA Ann Arbor Healthcare System, George Dock Professor of Internal Medicine, University of Michigan Medical School (U-M), discusses hospital-acquired infections and ways to prevent them.
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More